Methods of preventing protein aggregation

Abstract

Disclosed herein are methods and compositions for preventing or inhibiting amyloid complex formation of proteins that form pathological aggregates. Examples of these proteins include α-synuclein, tau protein, TDP-43, transthyretin, uromodulin, islet amyloid polypeptide (IAPP), serum amyloid A (SAA), p53, apolipoprotein E (APOE), APOE-4, prion protein, fibrin, or neurofilament light (NFL), CRP, SUMO, light chain, platelet-derived growth factor receptor (PDGFR), melanoma cell adhesion molecule (MCAM), complement proteins C3 and/or C9, lysozyme, insulin, native haemoglobin (Hb), glycosylated haemoglobin (HbAIC), phenylalanine (Phe), glutamine (Gln), cholesteryl (co-esteryl), cholesterol, neuroserpin, Crystallin AA and/or Crystallin AB, cystatin-C, and myostatin propeptide. These methods and compositions involve antibodies or binding fragments thereof that bind to galectin-3 (Gal3).

Dependencies are inferred from the claim text.